EGFR and non-small cell lung carcinoma: Mutations in the TK domain of the EGFR have been identified in some patients with refractory NSCLC who achieved good responses to gefitinib (Cappuzzo et al, 2004; Lynch et al, 2004; Pao et al, 2004).